Evidence map›Paper›PMID 42568479›Full record

ArticleFrontiers in immunology2026

Conserved CD4 T-cell responses correlate with antibody neutralization in solid organ transplant recipients after bivalent SARS-CoV-2 vaccination.

Georgia Stavrakis, Katerina Roznik, Laila Stoddart, T Scott Johnston, Snigdha Panda, Camille Hage, Aura T Teles, Yolanda Eby, William A Werbel, Aaron A R Tobian and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Georgia StavrakisDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Katerina RoznikDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Laila StoddartDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
T Scott JohnstonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Snigdha PandaDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Camille HageDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Aura T TelesDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Yolanda EbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
William A WerbelDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Aaron M MilstoneDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Alba GrifoniCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.
Andrew H KarabaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Elizabeth A ThompsonDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Andrea L CoxDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
HOPE in Action: A Clinical Trial of HIV-to-HIV Liver TransplantationU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2018 to 2026
$25.5M
Virology Resource CoreU54CA260492 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, SABRA L. · 2020 to 2024
$10.4M
Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2K08AI156021 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARABA, ANDREW HOOVER · 2021 to 2025
$994k
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
NCI NIH HHS U54 CA260492NIAID NIH HHS K08 AI156021NIAID NIH HHS K23 AI157893NIAID NIH HHS U01 AI138897NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

Introduction: Vaccines against SARS-CoV-2 and influenza require reformulation due to viral evolution. It remains unclear how vaccination against evolving antigens influences T-cell responses and the impact of reformulation on T-cell responses to new variants in immunocompromised hosts. Solid organ transplant recipients (SOTRs) had significantly lower antibody levels following vaccination and required repeated boosting during the COVID-19 pandemic. Methods: With the introduction of the Omicron spike (S) to the bivalent mRNA vaccines in 2022, the relative contribution of T-cell responses cross-reactive for Omicron mutated S sequences was assessed via intracellular cytokine staining using peptide pools containing conserved or mutated S sequences. Results: S-specific CD4 T cells recognize both conserved and Omicron mutated S sequences pre- and post-bivalent vaccination, even in the absence of evidence of prior infection as detected by T-cell responses to a novel peptide pool. CD4 T-cell responses to both conserved and Omicron mutated sequences correlated with antibody pseudo-neutralization of BA.5 S. Importantly, pre-bivalent conserved S CD4 T-cell responses significantly correlated with antibody pseudo-neutralization of BA.5 S post-bivalent. Discussion: These results emphasize the importance of conserved and cross-reactive responses in vaccine immunogenicity, providing a mechanism through which repeated boosting enhances vaccine immunogenicity in SOTRs and other immunocompromised populations.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCOVID-19COVID-19 VaccinesSARS-CoV-2BNT162b5BNT162 VaccineCross ReactionsHumansImmunocompromised HostOrgan TransplantationSpike Glycoprotein, CoronavirusTransplant RecipientsVaccinationAntibodies, NeutralizingAntibodies, ViralBNT162b5BNT162 VaccineCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19immunocompromisedmemoryT cellsvaccines

Identifiers

PMID42568479
PMCPMC13447162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.